CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
ENK Cell Infusiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01884688
NCT01884688Phase 2Completed
CompareCT.gov

A Phase II Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

University of Arkansas·interventional·Posted Jun 24, 2013·Updated Apr 17, 2017

In Brief

A Phase 2 clinical trial evaluating ENK Cell Infusion for Asymptomatic Multiple Myeloma. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsymptomatic Multiple Myeloma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 24, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.0 years ago

Interventions

ENK Cell Infusiondrug

Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU